ICB · NHS GLP-1 access
Bath, North East Somerset, Swindon and Wiltshire: NHS GLP-1 access
NHS Bath and North East Somerset, Swindon and Wiltshire ICB (BSW) is the NHS England Integrated Care Board for Bath, Swindon, Salisbury and the surrounding area, serving approximately 0.95 million people across the South West region. NICE Mounjaro rollout under TA1026 is operationalised here through the local Specialist Weight Management Service. Cohort 1 (BMI 40+ with 4+ comorbidities) is live nationally since June 2025; Cohort 2 launches across England on 23 June 2026.
Region
South West
Population served
~0.95m
ICB abbreviation
BSW
Major areas covered
Bath · Swindon · Salisbury · Chippenham · Trowbridge
Mixed-density patch combining historic cities, market towns, and rural communities; broadly middle of the pack on specialist service capacity.
Rollout cohort framework (national)
- Cohort 1 (live since June 2025): BMI 40+ (37.5+ with ethnicity adjustment) and four or more weight-related comorbidities. Operationalised through Specialist Weight Management Service referral.
- Cohort 2 (launches 23 June 2026): BMI 35+ (32.5+ with ethnicity adjustment) and three or more comorbidities.
- Cohort 3 (expected April 2027): BMI 30+ (27.5+ with ethnicity adjustment) and two or more comorbidities.
Local pace varies. Some ICBs commissioned tier-3 capacity ahead of June 2025 and ran ready; others took six to twelve months to scale. Capacity at the local Specialist Weight Management Service is the binding constraint in most areas. PeptideClear\'s central rollout tracker documents known pace data per region; per-ICB granular data is added as ICBs publish.
How NHS referral works in Bath, North East Somerset, Swindon and Wiltshire
The standard NHS pathway for patients meeting current-cohort criteria starts with the GP. The GP confirms BMI, ethnicity adjustment where applicable, and comorbidity count, then refers to the local Specialist Weight Management Service. The service runs the assessment, prescribes the medication if the patient is suitable, and provides the structured 12-month programme that includes lifestyle support alongside the medication.
Stopping rule: patients must achieve at least 5 percent weight loss from baseline by month 6 for NHS Mounjaro to continue under TA1026. Private prescribing operates outside this stopping rule and follows its own continuation criteria.
Private alternatives
Private prescribing operates independently of the NHS cohort framework. UK clinics and pharmacies can prescribe tirzepatide and semaglutide based on their own clinical criteria, typically aligned to MHRA SPCs (BMI 30+ for Wegovy, BMI 30+ for Mounjaro weight management, BMI 27+ with comorbidities).
- · High-touch UK clinics (Numan, Voy, Manual, Juniper) bundle prescribing with coaching from £199 to £299 per month.
- · Low-touch UK pharmacies (Phlo, SimplyMeds, Boots Online Doctor, Asda Online Doctor, Pharmacy2U) dispense via questionnaire from £149 per month.
- · UK delivery is nationwide from all listed providers. The provider does not have to be in the same ICB as the patient.
Neighbouring ICBs
Background reading
- · NHS GLP-1 access explained
- · NICE TA1026 explained
- · Ethnicity-adjusted BMI thresholds
- · Central ICB rollout tracker
- · All 42 ICBs
- · NHS access editorial hub
PeptideClear is editorial. We do not prescribe, dispense, or sell prescription medication. Your prescriber decides what medication and dose suits you.